Cuban lung cancer medicine receives Innovation Award
The product shows positive results in prolonging and improving the quality of patients’ lives

Author: Orfilio Peláez | orfilio@granma.cu
november 19, 2015 09:11:14

 

 

 

 

 

 

 

 

 

 

 

The medication Vaxira to treat advanced large cell lung cancer is developed by Cuba’s Molecular Immunology Center. Photo: Yaimí Ravelo

The medication Vaxira to treat advanced large cell lung cancer, developed by Cuba’s Molecular Immunology Center, received the Prize for Creativity and Technological Innovation 2015, awarded by the Cuban Industrial Property Office (OCPI).
Registered in Cuba since 2012 after being approved by the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed), the product shows positive results in prolonging and improving the quality of patients’ lives, and has low toxicity levels resulting in less of the unpleasant side effects associated with other necessary therapeutic procedures.
The safety of the product allows it to be administered over long periods of time through the primary healthcare system, and is also suitable for elderly people suffering from the disease.
Vaxira is patented in 17 countries, while clinical trials are currently underway to assess its possible use in treating varieties of breast and ovarian cancer